| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
 
|
|
|
||
|
|
© 2001 International Anesthesia Research Society
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
We tested the effect of epinephrine added to 20 mL ropivacaine 0.5% and 0.2% on postoperative analgesia via a femoral catheter after total knee replacement. Forty-one patients undergoing total knee replacement under combined peripheral block/general anesthesia were randomly allocated to two groups. After insertion of a femoral catheter, 21 patients in the Ropivacaine-Epinephrine (ROPI-EPI) group received 20 mL ropivacaine 0.5% plus epinephrine 1:200,000, whereas 20 patients in the Ropivacaine group (ROPI) received 20 mL plain ropivacaine 0.5%. Thereafter, a sciatic block with 30 mL bupivacaine 0.5% plus epinephrine 1:200,000 was performed in all patients, followed by general anesthesia. After surgery, patient-controlled analgesia (PCA) with ropivacaine 0.2% plus epinephrine 1:200,000 for Group ROPI-EPI and plain ropivacaine 0.2% for Group ROPI was available via the femoral catheter (200 mL ropivacaine 0.2% ± epinephrine, bolus 20 mL, lockout 120 min). The patients were instructed to use PCA when the knee pain score was >3 cm. The interval between the initial ropivacaine injection and the first PCA injection determined the duration of 20 mL ropivacaine 0.5% ± epinephrine, whereas the interval between the first and second PCA injection determined the duration of 20 mL ropivacaine 0.2% ± epinephrine. The average duration of ropivacaine 0.5% was 657 ± 345 min for the ROPI-EPI group and 718 ± 423 min for the ROPI group (NS), whereas for ropivacaine 0.2%, the average duration was 409 ± 245 min for the ROPI-EPI group and 419 ± 339 min for the ROPI group (not significant). We conclude that epinephrine does not influence the duration of analgesia of the ropivacaine concentrations investigated.
IMPLICATIONS: We evaluated the effect of epinephrine on the duration of analgesia of 20 mL ropivacaine 0.5% or 0.2% injected in femoral three-in-one block for pain relief after total knee replacement. Our results show that epinephrine does not alter the duration of analgesia of the two solutions investigated.
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Total knee replacement (TKR) generates severe postoperative pain (1). For this surgical procedure, postoperative analgesia with a peripheral nerve block or epidural technique is superior to that obtained with IV opioids (2,3). Because of fewer side effects, peripheral nerve analgesia, when compared with epidural analgesia, seems to be the technique of choice for postoperative pain relief after TKR (2,3).
One recent study concluded that the intermittent administration of bupivacaine, when compared with continuous infusion via a femoral catheter patient-controlled analgesia (PCA) device, allows decreases in the local anesthetic consumption without compromising pain scores (4). Although bupivacaine is the local anesthetic most frequently given, ropivacaine, being loss toxic than bupivacaine (5), seems more appropriate for prolonged administration via the femoral catheter.
Prolongation of ropivacaine action would be beneficial when this drug is given over days via an indwelling femoral catheter, because the total dose of ropivacaine administered, and thus the risk of toxic effects, could be further decreased. Epinephrine is added to local anesthetics to prolong the duration of spinal or epidural anesthesia. During epidural anesthesia, epinephrine has not altered the duration of ropivacaine 0.5% and 0.75% in humans (6) or of ropivacaine 1% in animals (7). In volunteers, the addition of epinephrine does not improve latency or duration of 2 mL ropivacaine 0.25%, 0.5%, 0.75%, or 1% in ulnar nerve block (8). In axillary blocks, epinephrine prolongs the anesthetic action of 40 mL lidocaine 1% (9), whereas the addition of epinephrine to 33 mL of ropivacaine 0.5% does not affect the characteristics of the subclavian perivascular brachial plexus block (10). However, the effects of epinephrine mixed with smaller doses or concentrations of ropivacaine for postoperative analgesia are not known. This study was designed to test the effects of adding epinephrine to 20 mL of ropivacaine 0.5% and ropivacaine 0.2% for postoperative analgesia via a femoral catheter after TKR, the main end point being the duration of action.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
After institutional approval, 48 orthopedic patients, ASA class II–III, undergoing a TKR under combined peripheral block/general anesthesia, agreed to participate in this study. Exclusion criteria were hemorrhagic diathesis, peripheral neuropathy, allergy to amide local anesthetics, preoperative use of opioids, and mental disorders.
For premedication, the patients received midazolam 7.5 mg orally 30–45 min before scheduled arrival in the operating room. Standard monitoring included continuous electrocardiogram, arterial oxygen saturation, and noninvasive blood pressure measurement. A peripheral venous catheter was inserted in all patients, whereas urinary, central venous, and arterial catheters were placed only when required by the patient’s clinical condition.
All patients received fentanyl 1.5 µg/kg IV before the insertion of a femoral catheter (ContiplexD Set®; B.Braun, Melsungen, Germany). According to the landmarks of Winnie et al. (11), the femoral nerve was located by using a nerve stimulator (Dual Stim; Life-Tech, Houston, TX). After observing a contraction of the quadriceps femoris (patella ascension) with impulses <0.4 mA, the catheter was introduced in the femoral sheath 15 cm from the skin.
By using sealed envelopes, the patients were randomly assigned to one of the two study groups and received in a double-blinded fashion one of the following solutions via the femoral catheter: Group ropivacaine-epinephrine (ROPI-EPI), 20 mL of ropivacaine 0.5% (Naropin®; Astra, Dietikon, Switzerland) mixed with 0.1 mg of epinephrine (1:200,000) in 1 mL normal saline; and Group ropivacaine alone (ROPI), 20 mL ropivacaine 0.5% mixed with 1 mL normal saline. These study solutions were prepared by one attending anesthesiologist not responsible for the patient.
After the injection of the study solution, a sciatic block with 30 mL bupivacaine 0.5% (Carbostesin®; Astra) with epinephrine 1:200,000 was performed in all patients by using the anterior approach (12). A 100-mm-long needle was linked to a nerve stimulator, and the anesthetic solution was injected after obtaining dorsal or plantar flexion of the foot with impulses <0.4 mA.
Fifteen minutes after each injection of local anesthetic solution, the sensory block was assessed by loss of temperature discrimination with ether drops at the anterior knee (femoral) and anterior foot (sciatic) areas. The block was considered present when no cold feeling was observed, doubtful when cold feeling was decreased, and absent when normal cold feeling was observed.
General anesthesia was then induced with sodium thiopental 4–6 mg/kg and rocuronium 0.6 mg/kg. After tracheal intubation, anesthesia was maintained with isoflurane (end-tidal concentration, 0.3%–1%) and nitrous oxide 60%–70% in oxygen. During surgery, fentanyl 1 µg/kg was given when, with 1% end-tidal isoflurane concentration, heart rate, mean arterial blood pressure, or both increased more than 30% above the preinduction levels.
After surgery, PCA via the femoral catheter was available, with 200 mL ropivacaine 0.2% mixed with 1 mg (1 mL) epinephrine (1:200,000) for Group ROPI-EPI and 200 mL ropivacaine 0.2% mixed with 1 mL normal saline for Group ROPI. These study solutions were prepared by nurses in the recovery room not participating in data collection. The PCA device was set to deliver 20-mL boluses with a lockout at 120 min. All the patients were instructed to quantify the postoperative knee pain intensity on a visual analog scale (VAS) ranging from 0 to 10 cm and to locate pain when possible in either the anterior or posterior knee area; they were further instructed to use ropivacaine via the femoral PCA device when the pain score in the anterior knee area was >3 cm or to ask for rescue morphine in the event of persistent pain in the posterior knee area. The interval between the initial ropivacaine injection and the first PCA injection determined the duration of 20 mL ropivacaine 0.5% with or without epinephrine, whereas the interval between the first and the second PCA injection determined the duration of 20 mL ropivacaine 0.2% with or without epinephrine.
Pain scores at rest every 4 h after the initial ropivacaine injection and over 48 h were recorded by the nurses in charge. Intervals between initial ropivacaine injection (Time 0) and the first PCA injection and between the first and second PCA injections, as well as the consumption of ropivacaine 0.2% over 24 and 48 h, were recorded by one investigator blinded to the ropivacaine solution used. Sciatic sensory block was assessed at 24 h by loss of temperature discrimination with ether drops by the same investigator.
Rescue morphine (0.1 mg/kg subcutaneously, maximum six doses in 24 h) was prescribed if the residual pain score at the anterior knee area was higher than 3 cm during the lockout interval of the PCA pump or for pain in the posterior knee area. Paracetamol 1 g (Dafalgan®; UPSA, Baar, Switzerland), ibuprofen 400 mg (Brufen®; Knoll, Liestal, Switzerland), or both were given orally for other pain (headache, back pain, or arthritic pain) as required. Analgesic requirements over 48 h were checked from nurses’ records.
There was an a priori decision that a difference in the duration of analgesia of at least 40% would be regarded as clinically relevant. We wished the SDs of the estimated means of duration not to exceed 40% of the means. Thus, for a two-tailed test with unpaired data, 
= 0.05, and ß = 0.20, a minimum of 16 patients were required per group. Data are presented as mean ± SD and were compared by using the unpaired Student’s t-test or 
2 test, as required; P < 0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Seven of 48 patients enrolled were withdrawn from the study for the following reasons: partial failure of the femoral catheter in three patients, accidental removal of the femoral catheter immediately after surgery in two patients, and use of a PCA device incompatible with study design in two patients.
Among the remaining 41 patients, 21 had been allocated to the ROPI-EPI group and 20 to the ROPI group. Patient characteristics (Table 1) were comparable between the two groups.
|
Fifteen minutes after injection of local anesthetic in the ROPI-EPI group, sensory femoral block was present in 20 patients and doubtful in 1 patient, compared with 19 present and 1 doubtful in the ROPI group. Two patients with doubtful femoral block had a confirmed block in the recovery room and did not require morphine over 48 h. Sensory sciatic block was present in 19, doubtful in 1, and absent in 1 patient in the ROPI-EPI group. In the ROPI group, this block was present in 19 patients and doubtful in 1 patient. The patient with failed sciatic block did not receive morphine in the postoperative period.
Anesthesia characteristics are presented in Table 2 and were comparable between the two groups. One patient in each group received fentanyl for hypertension during cuff inflation, and the remaining patient in the ROPI group received fentanyl by mistake for movements immediately after the start of surgery, with an isoflurane end-expiration concentration of 0.4%. Twenty-four hours after initial injection, sensory sciatic block was present in 13 patients in the ROPI-EPI group and in 15 patients in the ROPI group.
|
The duration of analgesia for 20 mL ropivacaine 0.5% and 0.2%, the 24- and 48-h consumption of ropivacaine 0.2%, and the number of patients requiring rescue morphine are presented in Table 3 and were not different between groups. The average duration of 20 mL ropivacaine 0.5% was approximately 11 h for the ROPI-EPI group and 12 h for the ROPI group, whereas for 20 mL ropivacaine 0.2%, the average duration was approximately 7 h for both groups. Because of technical problems with the femoral catheter, four patients in the ROPI-EPI group and three patients in the ROPI group were not considered for analysis after 24 h. During the first 24 postoperative hours, morphine was given in all four patients (three in the ROPI-EPI group and one in the ROPI group) for posterior knee pain. Two patients in ROPI-EPI group received morphine after the second 20 mL ropivacaine 0.2% administration, and one patient in each group received morphine between the first and second ropivacaine doses. Between 24 and 48 postoperative hours, morphine was given in nine patients for posterior pain, in one for lateral pain (sciatic area), and in four for diffuse nonlocalized knee pain.
|
A comparable number of patients in each group received paracetamol during the first 24 h (19% in the ROPI-EPI group versus 35% in the ROPI group) and during the following 24 h (47% in the ROPI-EPI group versus 56% in the ROPI group). Ibuprofen requirements were comparable (19% vs 40% from 0 to 24 h and 53% vs 67% from 24 to 48 h).
The evolution of pain scores over 48 h after blockade is illustrated in Figure 1. The mean values remained <3 cm in both groups, and the differences were not significant.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we explored the effects of epinephrine on the duration of analgesic action of 20 mL ropivacaine 0.5% or 0.2% injected in femoral three-in-one block for pain relief after TKR. Our results show that epinephrine does not modify the duration of analgesia of the two solutions investigated.
We believe that the described analgesic management, including continuous femoral and long-lasting sciatic blocks, improved the accuracy of measurement of the duration of action of both ropivacaine solutions investigated. Because the knee joint receives nerve supplies from two different plexuses, it can sometimes be difficult for patients to distinguish pain sensations originating from the knee area that is dependent on either femoral or sciatic sensory fibers. The presence of a long-lasting sciatic block increases the probability that patients self-administer ropivacaine for pain arising from the anterior knee area; thus, the time of PCA administration allows precise determination of the duration of action of ropivacaine solutions. Indeed, sensory sciatic block was already present in 28 of 41 patients at 24 hours after blockade, which is much longer when compared with a maximum duration of 11–12 hours for ropivacaine injected in a femoral catheter. In one study that used continuous infusions of local anesthetic mixed with clonidine and morphine in the femoral sheath for postoperative analgesia after TKR, pain in the posterior knee area was clearly reported and recognized as disturbing for the patients (3).
Continuous femoral block associated with long-lasting single-shot sciatic block is a standard procedure in our institution in patients undergoing TKR under general anesthesia. Although the utility of an additional sciatic block for postoperative analgesia has been questioned (13), we have shown that this block, in addition to a continuous femoral block, improved postoperative pain relief in at least two thirds of the patients undergoing TKR under spinal anesthesia (14). Sciatic block performed before surgery probably contributed to the small perioperative analgesic requirements in our patients; these seem to be lower than when TKR is performed under general anesthesia with femoral block only (2,3). The mean VAS values lower than 1 cm during the first 16 postoperative hours (Fig. 1) in both groups further support the analgesic efficacy of sciatic block.
In this study, no effect of adding epinephrine to 20 mL ropivacaine 0.5% or 0.2%, in terms of improved analgesic duration, was detected. It is accepted that epinephrine prolongs the anesthetic action of 40 mL lidocaine 1% (short-acting local anesthetic) (9) but not of 33 mL ropivacaine 0.5% (considered long acting) (10). Using a smaller volume but mainly a smaller concentration (i.e., 0.5% vs 0.2%) of ropivacaine, we expected a prolongation of the duration of analgesia by adding epinephrine; this, however, was not the case. The mean duration of analgesia observed for both 20 mL ropivacaine 0.5% (12 h) and 20 mL ropivacaine 0.2% (7 h) is probably too long to be influenced by epinephrine. These findings are in agreement with previously published data studying the association of ropivacaine with epinephrine in peripheral blocks in both patients (10) and volunteers (8) or in epidural anesthesia in both patients (6) and animals (7).
Another possible explanation for the lack of effect of epinephrine could be the intrinsic vasoconstrictor property of ropivacaine (15). Thus, epinephrine added to ropivacaine in peripheral nerve blocks can be useful only for early detection of intravascular injection, which can be associated with serious complications (16,17).
Only intermittent injections of ropivacaine 0.2% by use of a PCA pump (20-mL bolus, 120-minute lockout) were prescribed in our patients. Recently, it has been shown that after TKR, boluses of 10 mL bupivacaine 0.125% with 1 µg/mL clonidine (lockout 60 minutes) were associated with a significantly smaller anesthetic consumption than when continuous infusions of 10 mL/h or continuous infusions of 5 mL/h plus boluses of 2.5 mL (lockout 30 minutes) of the same solution were used (4). Analgesic effects of these three study solutions and patient satisfaction were not different, confirming the advantage of intermittent administration of local anesthetics. In this study, we used larger boluses and longer lockout times. With or without epinephrine, approximately three boluses of 20 mL ropivacaine 0.2% were administered for the first 24 hours, and four or five were administered for the following 24 hours. The average consumption of ropivacaine 0.2% was 3–4 mL/h, which is consistent with previously described intermittent techniques (4) and much smaller than with continuous infusions (2,3,18).
Excellent pain control was obtained in all patients with the described analgesic management. Mean VAS scores never exceeded 2 cm during the first 24 hours and 3 cm in the following 24 hours in both study groups (Fig. 1). Morphine requirements during the first 24 hours were negligible; larger morphine consumption from 24 to 48 hours (Table 3) can be attributed to the resolution of sciatic block. Indeed, in the majority of patients, the morphine injections (10 of 14) were given for pain at the posterior or lateral knee area corresponding to sciatic innervation; the remaining four patients received morphine for diffuse knee pain. We did not test pain scores at mobilization, because in our institution postoperative knee mobilization starts 48 hours after surgery. Nevertheless, the femoral catheters were withdrawn only when the patients spontaneously stopped using the PCA pump, which generally occurred between the third and fifth postoperative day.
In conclusion, the results of this study show that epinephrine does not influence the duration of analgesia of either ropivacaine concentration investigated. Epinephrine added to ropivacaine can be useful only for early detection of intravascular injection. Nevertheless, the described peripheral analgesic technique provided excellent pain relief over 48 hours after TKR.
|
Footnotes |
|---|
Presented in part at the annual meeting of the American Society of Anesthesiologists, San Francisco, CA, October 14–18, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
- Bonica JJ. Postoperative pain. In: Bonica JJ, ed. The management of pain. 2nd ed. Philadelphia: Lea & Febiger, 1990: 461–80.
-
Singelyn FJ, Deyaert M, Joris D, et al. Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous three-in-one block on postoperative pain and knee rehabilitation after unilateral total knee arthroplasty. Anesth Analg 1998; 87: 88–92.
[Abstract/Free Full Text] - Capdevila X, Barthelet Y, Biboulet P, et al. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology 1999; 91: 8–15.[Web of Science][Medline]
-
Singelyn FJ, Gouverneur JM. Extended "three-in-one" block after total knee arthroplasty: continuous versus patient-controlled techniques. Anesth Analg 2000; 91: 176–80.
[Abstract/Free Full Text] -
Scott B, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–9.
[Abstract/Free Full Text] - Cederholm I, Anskär S, Bengtsson M. Sensory, motor, and sympathetic block during epidural analgesia with 0.5% and 0.75% ropivacaine with and without epinephrine. Reg Anesth 1994; 19: 18–33.[Web of Science][Medline]
- Hurley RJ, Feldman HS, Latka C, et al. The effects of epinephrine on the anesthetic and hemodynamic properties of ropivacaine and bupivacaine after epidural administration in the dog. Reg Anesth 1991; 16: 303–8.[Web of Science][Medline]
- Nolte H, Fruhstorfer H, Edström HH. Local anesthetic efficacy of ropivacaine (LEA 103) in ulnar nerve block. Reg Anesth 1990; 15: 118–24.[Web of Science][Medline]
- Martin R, Martin G, Martin D, et al. Effets du CO2 et de l’adrenaline sur la lidocaïne 1% dans le bloc axillaire. Ann Fr Anesth Réanim 1997; 16: 479–82.[Web of Science][Medline]
- Hickey R, Candido KD, Ramamurthy S, et al. Brachial plexus block with a new local anaesthetic: 0.5 per cent ropivacaine. Can J Anaesth 1990; 37: 732–8.[Web of Science][Medline]
-
Winnie AP, Ramamurthy S, Durrani Z. The inguinal paravascular technic of lumbar plexus anesthesia: the "3-in-1 block." Anesth Analg 1973; 52: 989–96.
[Free Full Text] - Beck GP. Anterior approach to sciatic nerve block. Anesthesiology 1963; 24: 222–4.[Web of Science][Medline]
-
Allen HW, Liu SS, Ware PD, et al. Peripheral nerve blocks improve analgesia after total knee replacement surgery. Anesth Analg 1998; 87: 93–7.
[Abstract/Free Full Text] - Weber A, Fournier R, Van Gessel E, Gamulin Z. Sciatic nerve block improves femoral nerve block analgesia after total knee replacement. Eur J Anaesthesiol 2000; 17 (Suppl 19): 340A.
- Kopacz DJ, Carpenter RL, Mackey DC. Effect of ropivacaine on cutaneous capillary blood flow in pigs. Anesthesiology 1989; 71: 69–74.[Web of Science][Medline]
- Korman B, Riley RH. Convulsions induced by ropivacaine during interscalene brachial plexus block. Anesth Analg 1997; 85: 1128–9.[Web of Science][Medline]
- Ruetsch YA, Fattinger KE, Borgeat A. Ropivacaine-induced convulsions and severe cardiac dysrhythmia after sciatic block. Anesthesiology 1999; 90: 1784–5.[Web of Science][Medline]
-
Ganapathy S, Wassweman RA, Watson JT, et al. Modified continuous femoral three-in-one block for postoperative pain after total knee arthroplasty. Anesth Analg 1999; 89: 1197–202.
[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
 |
|
  P. J. MacMahon, S. J. Eustace, and E. C. Kavanagh Injectable Corticosteroid and Local Anesthetic Preparations: A Review for Radiologists Radiology, September 1, 2009; 252(3): 647 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Liu and F. V. Salinas Continuous Plexus and Peripheral Nerve Blocks for Postoperative Analgesia Anesth. Analg., January 1, 2003; 96(1): 263 - 272. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
